Artiva Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- $248.6M
- Website
- http://www.artivabio.com
Artiva's AlloNK Shows Promising Durability in B-Cell Non-Hodgkin Lymphoma, Matching CAR-T Efficacy
• Artiva Biotherapeutics' AlloNK in combination with rituximab demonstrated a 64% complete response rate in heavily pretreated B-cell non-Hodgkin lymphoma patients, comparable to approved autologous CAR-T therapies.
• The median duration of response has not been reached and extends beyond 19.4 months, with a well-tolerated safety profile showing no cytokine release syndrome or neurotoxicity events.
• Results suggest AlloNK's potential for deep B-cell depletion in autoimmune diseases, with a safety profile compatible with outpatient administration in community settings.
© Copyright 2025. All Rights Reserved by MedPath